Of note, inactivating mutations in either gene arise with a markedly increased frequency in breast cancer patients treated with anti-endocrine therapy53,55, reflecting their function in mediating the repressive activity of ERα and tamoxifen sensitivity56. The gene discussed is ESR1; the disease is breast carcinoma.